What Happened to Oxford Biomedica plc Shares on 13 November 2026?

Oxford Biomedica plc (LSE:OXB) shares eased 1.50% to 527.0p on 13 November 2026. The cell and gene therapy manufacturer was in focus following its half-year results for the six months ended 30 June 2026, published on 22 September 2026.

The results reported higher revenue, record new client wins and a growing commercial pipeline.

Key Highlights

Revenue rose 10% at constant currency to £80.2m, with Manufacturing Revenue up 20%. The company signed 17 new clients in the half, more than 30% above the total signed in all of 2025, with four more after the period.

The client base reached 50 clients and 59 programmes, up 34% year on year.

About Oxford Biomedica plc

Oxford Biomedica, or OXB, is a contract development and manufacturing organisation for cell and gene therapies, with 30 years of experience in viral vectors. It works with pharmaceutical and biotechnology companies on lentivirus, adeno-associated virus and adenovirus vectors.

Frank Mathias is Chief Executive, and the group operates sites in the UK, France and the US.

Commercial Pipeline and Backlog

The commercial pipeline reached $730m at the half-year point, up 30% year on year, with the US representing 40% of pipeline opportunities in the third quarter. Revenue Backlog was £193m at 30 June, and £168m of forecast 2026 revenue was covered by contracted client orders.

Contracted orders rose from £97m at the half year to £127m by the end of August.

US Expansion

The Durham, North Carolina site is operationally ready and serving clients, with GMP manufacturing capabilities online and the first GMP run completed. The group also signed a commercial Supply agreement with Bristol Myers Squibb for lentiviral vectors.

Nine programmes had reached late-stage development or commercial status by the half year.

Financial Position

The group ended the first half with £75.3m of gross cash and net cash of £21.4m. Administration costs were 18% of revenue, down from 18.6% a year earlier, and the company targets low double digits by 2030.

Management expects some first-half Working Capital outflows to reverse in the second half.

Outlook and Ambitions

Full-year 2026 revenue guidance of £180m to £200m was reiterated, with revenue weighted to the second half. For 2027, the company targets revenue growth of 25% to 30% and EBITDA margins of at least double digits.

The longer-term ambition is revenue of £500m by 2030 with EBITDA margins approaching 30%.

Understanding CDMO and Viral Vectors

A CDMO develops and manufactures products on behalf of clients. Viral vectors are engineered viruses used to deliver genetic material into cells in gene and cell therapies.

Manufacturing revenue relates to batches produced, while development revenue relates to process development work.

Why the Update Matters for the Sector

Cell and gene therapy manufacturers are followed for client wins, programme progression and capacity utilisation. OXB's results show how a growing client base can feed pipeline and backlog.

The shift towards late-stage and commercial programmes is a key theme for the sector.

Putting the Update in Context

Revenue in these businesses can include product sales, service fees and milestone payments, and companies explain how each is recognised. Cash balances and funding runway are routine parts of reporting, helping readers understand how programmes are supported.

Regulatory approvals, quality standards and manufacturing capacity are standard topics in healthcare announcements. Management commentary on these areas shows how a company plans to meet Demand from customers and partners.

Key Growth Catalysts

New client wins, progression of programmes to late stage and commercial supply, and the Durham site are the main supports. A growing backlog gives visibility on future revenue.

Cost discipline contributes to Margin progress.

Factors to Monitor

Client ordering and programme timelines can shift revenue between periods. Capacity utilisation and the ramp-up of new sites influence profitability.

Second-half weighting means timing matters for the full-year outcome.

What Investors Should Watch Next

Investors may wish to follow second-half revenue delivery, backlog conversion, Durham utilisation and 2027 guidance.

Conclusion

Oxford Biomedica plc (LSE:OXB) eased 1.50% to 527.0p on 13 November 2026. Oxford Biomedica reported 10% constant currency revenue growth, record client wins and a $730m pipeline. Second-half delivery is the next point of reference.